← Eichor
Study identifier: NCT07459101 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

UNIty-Based MR-Linac Guided Adaptive RadioThErapy for High GraDe Glioma-4

Condition: Glioblastoma (GBM) · Astrocytoma, Grade IV  ·  Sponsor: Sunnybrook Health Sciences Centre

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study builds on the results of prior studies (UNITED and UNITED-3). The goal of UNITED-4 is to test whether an adaptive radiation therapy (RT) therapy approach ('dose painting'), with reduced margins, impacts approach in participants with glioblastoma impacts local control compared to standard non-adaptive RT approach. The main questions of the study are to see how this adaptive RT approach with reduced margins compares to standard RT in terms of: * Local control * Overall and progression-free survival * Patterns of failure * Toxicity, Neurological Function, and Quality of Life * Longitudinal imaging features

This description comes directly from the study's public registry record.

Talk to the study team

Hanbo Chen, MD  ·  416-480-6100  ·  hanbo.chen@sunnybrook.ca

Always discuss trial participation with your own doctor first.

Locations (1)

Sunnybrook Health Sciences Centre - Odette Cancer CentreToronto, Ontario, CanadaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07459101